Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

David Harlan

Endocrinology, Diabetes & Metabolism Worcester, MA Medical Doctor

NPI 1083737951 CMS profile 139757

55 Lake Ave N, Ambulatory Care Center, Room Ac4.127, Worcester, MA 01655

Open in the dashboard

General payments

$1,659

7 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,180 paid to institutions, not to them · program year 2021

Through program year 2025, David Harlan of Worcester, MA is reported in the CMS Open Payments database as having received $1,659 across 7 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,180 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 50th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $200 4
2022 General $400 1
2020 General $1,059 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Harlan
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to David Harlan were reported at $200. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year David Harlan Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $0 $494 $123–$2,253 $163
2020 $1,059 $335 $85–$1,841 $114
2021 $0 $398 $88–$1,981 $132
2022 $400 $364 $88–$1,568 $149
2023 $0 $420 $113–$1,614 $160
2024 $0 $440 $121–$1,646 $164
2025 $200 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Abbott Laboratories $1,000 1 payment
  2. Vertex Pharmaceuticals Incorporated $600 5 payments
  3. Mannkind Corporation $59 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Education $1,000 1 payment
  2. Consulting Fee $400 1 payment
  3. Food and Beverage $200 4 payments
  4. Gift $59 1 payment
Products named General payments · program years 2020–2025
  1. FreeStyle Lite system $1,000 1 payment
  2. AFREZZA $59 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

62

Median for Endocrinology: 1,959

Drug cost

$33,112

Median for Endocrinology: $890,201

Branded share of claims

53.2%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 33 $32,138
Ezetimibe Generic 11 $836
Atorvastatin Calcium Generic 18 $138

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Records

7 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record